Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › GLENMARK

GLENMARK

Glenmark Pharmaceuticals Limited
Mid-capPharma ↗

What the six lenses say about GLENMARK — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹2267.2
2026-07-10
VWAP · 1Y anchor
₹2079
+9.1% from VWAP
P/E · TTM
47.0×
TTM EPS ₹48.3
52-week range
76%
position low→high
RSI(14)
57
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How GLENMARK’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.0
avg conviction decile
Leadership
0/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD660›

The actual numbers

Price vs VWAP (1y)+9.1%
EMA trend stackMixed
Price vs 200-EMA+8.7%
Price vs 50-EMA+2.2%
RSI(14)57
RS vs Nifty 500 · 3M+1.5%
RS vs sector · 3M-10.9%
52-week range76%
Volume vs 30d avg0.87×
Volume vs 60d avg0.85×
ATR(14) · volatility67.8
Bollinger width · vol contraction0.071
FundamentalD974›

The actual numbers

Return on equity (ROE)30.5%
Return on capital (ROCE)39.8%
Operating margin12.9%
Net margin8.0%
Revenue growth · YoY+27.5%
EPS growth · YoY+30.1%
Debt / equity0.06×

Full 8-quarter history in the financials table below.

ValuationD313›

The actual numbers

P/E (TTM)47.0×
TTM EPS₹48.3
52-week range76%
CatalystD1067›

The actual numbers

Earnings & momentum97
Capital actions14
Governance64

Every filing in the corporate-announcements panel below.

FlowD450›

The actual numbers

Promoter holding46.6%
Delivery · 30d avg45.1%
Up/down-day asymmetry1.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D6 + D4 ) ÷ 2 = 5.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · High
59
Conviction score 59/100 · avg-decile strength 5.0/10
Conviction score59/100›
TechnicalD6›
FundamentalD9›
ValuationD3›
CatalystD10›
FlowD4›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+1.6pp
+4.1pp
+2.5pp
+5.2pp
+19.7pp
+24.6pp
Nifty 500
Broad-market baseline
+1.2pp
+4.0pp
+1.9pp
+1.5pp
+14.6pp
+20.7pp
Sector
Own-sector index
—
—
-0.5pp
-10.9pp
+0.2pp
+2.9pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

GLENMARK daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
2267.20+43.50

Relative strength

RS vs baseline · rebased to 100

GLENMARK ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
163.57+1.93

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)3,2443,4343,3883,2563,2646,0473,9013,771
↳ change QoQ—+5.8%-1.3%-3.9%+0.2%+85.3%-35.5%-3.3%
EBITDA (₹cr)6206416315615812,360870763
EBITDA margin19.1%18.7%18.6%17.2%17.8%39.0%22.3%20.2%
PAT (₹cr)340354348447610403301
↳ change QoQ—+4.2%-1.8%-98.9%+1075.0%+1197.9%-33.9%-25.3%
Net margin10.5%10.3%10.3%0.1%1.4%10.1%10.3%8.0%
EPS (₹)12.0612.5512.330.161.6621.6314.2910.68
D/E————————
YoY growth · Mar '26Revenue +15.8% YoYPAT +7425.0% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 17 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 11 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 9 Jun '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 5 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 1 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMgovernance
    Resignation of Director/KMP/SMP
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMcapital
    Dividend
    ›

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗
  • 29 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 29 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds GLENMARK

Mutual funds holding GLENMARK (10)

FundWeightAUM ₹crGrade
HDFC Mid Cap Gr3.13%97,350
HDFC Large and Mid Cap Gr0.84%28,515
Bandhan Small Cap Reg Gr0.77%27,219
Bandhan Large & Mid Cap Gr1.26%17,461
Invesco India Mid Cap Gr3.42%12,397
UTI Mid Cap Reg Gr0.82%12,122
Invesco India large& mid cap Gr3.01%10,153
Axis Multicap Reg Gr0.50%9,938
Mahindra Manulife Multi Cap Reg Gr1.27%6,643
UTI Large & Mid Cap Reg Gr0.95%6,218

ETFs holding GLENMARK (10)

ETFWeightGrade
Nippon India Nifty Pharma ETF3.59%
DSP Nifty Healthcare ETF3.30%
Aditya BSL Nifty Healthcare ETF3.30%
Axis NIFTY Healthcare ETF3.30%
ICICI Pru Nifty Healthcare ETF3.05%
Mirae Asset Nifty 500 Healthcare ETF2.72%
Motilal Oswal BSE Healthcare ETF2.31%
Motilal Oswal Nifty Midcap150 Momt 50ETF1.98%
Kotak Nifty 200 Momentum 30 ETF1.58%
Groww Nifty 500 Momentum 50 ETF1.16%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma